Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)

NCT04301076 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04301076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04301076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
August 31, 2021
Completion date
June 30, 2027
Enrollment
30 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

acute adult t-cell leukemia/lymphoma, adult t-cell leukemia/lymphoma, chronic adult t-cell leukemia/lymphoma, htlv-1 infection